2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 836

Comprehensive Behavioral Intervention Compared To Standard Of Care Exercise Program After Total Knee Arthroplasty: A Pilot Randomized Trial
Abstract Number: 2323

Comprehensive Disease Remission Achieved By Certolizumab Pegol Treatment, and Factors Associated With Certolizumab Pegol Comprehensive Disease Remission, In Rheumatoid Arthritis Patients With Predominantly High Disease Activity
Abstract Number: 1967

Computer-Aided and Manual Quantifications Of MRI Synovitis, Bone Edema, Erosion and Semi-Quantitative Cartilage Loss In Rheumatoid Arthritis
Abstract Number: 2365

Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Abstract Number: 1058

Concomitant Methotrexate Use and The Risk Of Drug Discontinuation For Adalimumab Compared With Etanercept In Anti-TNF-Naïve Rheumatoid Arthritis Patients: A Nationwide Population-Based Cohort Study
Abstract Number: 1120

Concordance Between ‘a Positive MRI Of The Sacroiliac joints’ Based On The Local Reading Versus a Centralised Reading: Experience From The DESIR-Cohort
Abstract Number: 261

Concordance Of Hip Pain With Radiographic Hip Osteoarthritis In An Urban US Community: The Framingham Osteoarthritis Study
Abstract Number: 2556

Concordance Of Indirect Immunofluorescence and Multiplex Immunoassay For Measurement Of Antinuclear Antibodies
Abstract Number: 1638

Concurrent Autoimmune Disease and Autoantibodies In a Large, Multi-Racial Cohort Of First Degree Blood Relatives Of SLE Patients
Abstract Number: 2357

Confounding By Indication Distorts The Relationship Between Steroid Use and Cardiovascular Disease In Rheumatoid Arthritis
Abstract Number: 2038

Congenital Heart Block Related With Maternal Autoimmune Diseases: Descriptive Analysis Of a Series Of 17 Cases
Abstract Number: 1373

Connective Tissue Growth Factor Promotes Angiogenesis Through Increased Notch-1 Signaling in Rheumatoid Arthritis
Abstract Number: 1566

Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus
Abstract Number: 417

Consensus Statement On The Diagnosis and Management Of Comorbidity In Rheumatoid Arthritis
Abstract Number: 2179

Consensus: What Agent To Use When First-Line Vasodilatadors Fail In Raynaud´s Phenomenon Or Digital Ulcers Secondary To Juvenile Systemic Sclerosis?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].